Results 1 to 10 of about 216,339 (397)

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer [PDF]

Nature Medicine, 2004
Dan G Duda, Lance L Munn, Daniel C Chung
exaly   +3 more sources

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

New England Journal of Medicine, 2020
BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, open-label, phase 3 trial, patients with
, Shukui Qin, Masafumi Ikeda
exaly   +2 more sources

Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients [PDF]

Cancer Immunology, Immunotherapy
Background Interstitial pneumonitis (IP) is a severe adverse event in patients receiving immunotherapy. Although PD-1/PD-L1 inhibitors and bevacizumab have been widely used in patients with non-small cell lung cancer (NSCLC), the interaction between ...
Linling Wang, Yasi Xu, Yanyan Zhao, Bing Xia, Lucheng Zhu   +4 more
doaj   +2 more sources

Lomustine and Bevacizumab in Progressive Glioblastoma

New England Journal of Medicine, 2017
Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies.
W. Wick, T. Gorlia, M. Bendszus, M. Taphoorn, F. Sahm, I. Harting, A. Brandes, W. Taal, J. Dômont, A. Idbaih, M. Campone, P. Clement, R. Stupp, M. Fabbro, É. Le Rhun, F. Dubois, M. Weller, A. von Deimling, V. Golfinopoulos, Jacoline E. C. Bromberg, M. Plattén, M. Klein, M. J. van den Bent   +22 more
semanticscholar   +6 more sources

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Nature Communications, 2016
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefit beyond a subset of patients. In preclinical models tumour-derived VEGF limits immune
Johanna C Bendell, Konstanty Korski, Suzanne Jones   +2 more
exaly   +2 more sources

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study [PDF]

Journal for ImmunoTherapy of Cancer
Background Options remain limited for patients requiring later lines of therapy for metastatic non-small cell lung cancer (mNSCLC) due to poor prognosis and potential toxicities.
Enriqueta Felip, Francois Ghiringhelli, Alona Zer, Byoung Chul Cho, Sun Min Lim, Laurent Greillier, Alastair Greystoke, Nuria Pardo, Yaacov R Lawrence, Nedal Al-Sakaff, Hans-Joachim Helms, Hen Prizant, Jan Pintoffl, Farah Louise Lim   +13 more
doaj   +2 more sources

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Nature Medicine, 2018
David F Mcdermott, Mahrukh A Huseni, Michael B Atkins   +2 more
exaly   +2 more sources

Bevacizumab [PDF]

The Oncologist, 2010
AbstractLearning ObjectivesAfter completing this course, the reader will be able to: Evaluate the clinical use of bevacizumab, both for cancer and for non-oncologic diseases, and discuss approved and investigational combination chemotherapies that include bevacizumab.Describe the pharmacology of bevacizumab and its mechanism of action in order to ...
Kazazi-Hyseni, F., Beijnen, J.H., Schellens, J.H.M.   +2 more
openaire   +6 more sources

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Journal of Clinical Oncology, 2007
B. Giantonio, P. Catalano, N. Meropol, P. O'dwyer, E. Mitchell, S. Alberts, M. Schwartz, A. Benson   +7 more
exaly   +2 more sources

Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer

Autophagy, 2023
Bevacizumab plays an important role in the first and second line treatment for metastatic colorectal cancer (CRC). And induction of hypoxia and the tumors response to it plays an important role in determining the efficacy of antiangiogenic therapy while ...
Weihao Li, Chi Zhou, Longjiang Yu, Zhenlin Hou, Huashan Liu, Lingheng Kong, Yanbo Xu, Jiahua He, Jin Lan, Q. Ou, Yujing Fang, Zhen-Hai Lu, Xiaojun Wu, Z. Pan, Jianhong Peng, Junzhong Lin   +15 more
semanticscholar   +1 more source